



Republic of Serbia
**COMMISSION FOR PROTECTION
OF COMPETITION**

Number: 6/0-02-603/2015-10

Date: November 20, 2015

Belgrade

Pursuant to Article 37(2) of the Law on Protection of Competition (Official Gazette of the RS 51/09 and 95/13), Article 192(1) of the Law on General Administrative Procedure (Official Gazette of the FRY 33/97 and 31/01, and Official Gazette of the RS 30/10), and Article 2(1/6) of the Tariff on the level of compensations for activities within the competence of the Commission for Protection of Competition (Official Gazette of the RS 49/2011), deciding under the Notification on concentration entered under number: 6/0-02-603/2015-1 of August 11, 2015 submitted by company Teva Pharmaceutical Industries Ltd, with registered seat at the address 5 Basel Street, Petach Tikva 4951033, Israel, via attorney at law Srđana Petronijević from the Law Office „Moravčević, Vojnović & Partneri“ from Belgrade, 15 Dobračina St., on November 20, 2015, President of the Commission for Protection of Competition enacts the following

DECISION

I Concentration of undertakings in summary procedure **IS APPROVED** created by acquisition of control on the part of company Teva Pharmaceutical Industries Ltd, with registered seat at the address 5 Basel Street, Petach Tikva 4951033, Israel, founded and registered in accordance with the Israeli legislation under company registration number 520013954, over global business operations involving generic pharmaceuticals of company Allergan Plc, with registered seat at the address Clonshaugh Business and Technology Park, Coolock, Dublin, D17 E400, Ireland, registered in the Companies Registration Office of Ireland under company registration number 527629, including the USA and international commercial units for generic pharmaceuticals, third party supplier Medis, global operations for production of generic pharmaceuticals, global unit for research and development of generic pharmaceuticals, international commercial unit for over-the-counter products (including eye care medications issued over-the-counter) and certain renowned international brands.

II IT IS ESTABLISHED that the applicant of notification on concentration has executed payment in the amount of EUR 25,000.00 (in words: twenty-five thousand and 00/100 euro) to the foreign-currency account of the Commission for Protection of Competition maintained with the National Bank of Serbia, which represents determined amount of the fee as compensation for issuing decision on approval of concentration in summary procedure from Article 2(1/6) of the Tariff on the level of compensation for activities within the competence of the Commission for Protection of Competition.